Spread | 0.2336 | ||||
Long position overnight fee Long position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
Overnight fee time | 21:00 (UTC) | ||||
Currency | USD | ||||
Min traded quantity | 0.01 | ||||
Margin | 20 | ||||
Stock exchange | United States of America | ||||
Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
Prev. Close | 5.3182 |
Open | 5.3682 |
1-Year Change | 454.11% |
Day's Range | 5.3682 - 5.3682 |
Pluristem Therapeutics Inc. is a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The Company's lead indications are critical limb ischemia (CLI), recovery after surgery for femoral neck fracture and acute radiation syndrome. Its operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. The Company's products include PLX-PAD and PLX R18. The Company's PLX cells are adherent stromal cells (ASCs) that are expanded using a three dimensional (3D) process. The system utilizes a synthetic scaffold to create an artificial 3D environment where placental-derived stromal cells can grow. The Company's PLX products are administered using a standard needle and syringe. The Company's PLX products are in clinical-stage development for multiple indications, such as cardiovascular, orthopedic, pulmonary and women's health diseases.
BRIEF: For the six months ended 31 December 2021, Pluristem Therapeutics Inc. revenues was not reported. Net loss increased 6% to $22.4M. Higher net loss reflects General and administrative expenses increase of 30% to $4.8M (expense), Stock-based Compensation in SGA increase of 9% to $4.6M (expense), Research & Development Expense decrease of 75% to $72K (income). Basic Earnings per Share excluding Extraordinary Items increased from -$0.82 to -$0.70.
Common Stock $0.00001 Par, 01/13, 100M auth., 58,333,206 issd. Insiders control 11.74%. IPO: NA. 11/07,1-for-200 reverse stock split. 11/07, Name changed from Pluristem Life Systems, Inc. 12/07, Exchanged changed from OTC Bulletin Board to NASDAQ.